NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Vertex is moving to high-grade production at its Reward gold mine as stoping gets underway at the 1670 airleg stope Over the last five days, 125t has been mined and processed Multiple mining fronts ...

Vertex Pharmaceuticals Incorporated is downgraded from Buy to Hold due to mounting headwinds and pipeline uncertainties. Vertex faces pressure from potential U.S. drug pricing reforms and tariffs, ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vertex Minerals Ltd. ( (AU:VTX)) just ...

BOSTON, September 11, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this ...

Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multitarget drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biopharmaceutical company with a market capitalization of over $100 billion specializing in cystic fibrosis (CF) treatments and expanding into other ...

Vertex Pharma ceuticals CEO Reshma Kewalramani bought a big chunk of the biotech’s stock earlier this month. The move, her first open-market purchase in years, appears to be a show of confidence in ...

The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Vertex Pharmaceuticals stock was among the worst performer in the S&P 500 index early Tuesday after the drugmaker said it wouldn’t advance its next-generation pain medicine to late stage trials.

Aug 4 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic fibrosis drug and product launches.